Sight Sciences raises $10m in Series C

Ophthalmic medical device company Sight Sciences said this week it closed a $10 million oversubscribed Series C round to support expanding manufacturing and its US commercial team and the launch of its devices into the dry eye and microinvasive surgery markets. The round was led by Allegro Investment Fund and was joined with full participation from existing Series A and Series B investors, the Menlo Park, Calif.-based company said. As part of the funding around, Allegro’s chairman Steffan Encrantz will join the company’s board of directors as chair. Funds are also slated to support expanding the company’s product indications and strategic product positioning. “Allegro has supported Sight Sciences from the beginning, and we have witnessed its technology platforms mature into breakthrough products that eye care providers confidently use to care for their patients. We look forward to supporting the Sight team as they work to elevate the standard of care globally in both glaucoma and dry eye, two diseases in need of high-yield innovation and more effective solutions,” Allegro Investment chair Encrantz said in a press release. “We are excited to partner with Allegro and welcome Staffan Encrantz to our board of directors as Chairman. Allegro is a skilled growth investor with a long-term view and strong history of supporting innovative companies like Sight Sciences as we achieve commercial scale and market leadership,” prez & CEO Paul...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Optical/Ophthalmic Sight Sciences Source Type: news